NASDAQ:CTMX CytomX Therapeutics (CTMX) Stock Price, News & Analysis $1.20 +0.02 (+1.69%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.19▼$1.2350-Day Range$1.12▼$1.5152-Week Range$1.04▼$5.85Volume983,712 shsAverage Volume3.02 million shsMarket Capitalization$93.50 millionP/E Ratio6.00Dividend YieldN/APrice Target$5.77 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get CytomX Therapeutics alerts: Email Address CytomX Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside381.0% Upside$5.77 Price TargetShort InterestBearish10.10% of Shares Sold ShortDividend StrengthN/ASustainability-0.74Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$24,677 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.20) to ($0.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.64 out of 5 starsMedical Sector222nd out of 910 stocksPharmaceutical Preparations Industry95th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingCytomX Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCytomX Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about CytomX Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.10% of the outstanding shares of CytomX Therapeutics have been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in CytomX Therapeutics has recently increased by 1.68%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytomX Therapeutics has received a 74.21% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for CytomX Therapeutics is -0.74. Previous Next 0.6 News and Social Media Coverage Search Interest12 people have searched for CTMX on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,677.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CytomX Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.20) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is 6.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.44.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is 6.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 112.07.Read more about CytomX Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] About CytomX Therapeutics Stock (NASDAQ:CTMX)CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Read More CTMX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTMX Stock News HeadlinesAugust 23, 2024 | insidertrades.comInsider Selling: CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sells 13,898 Shares of StockAugust 28, 2024 | americanbankingnews.comCytomX Therapeutics' (CTMX) Neutral Rating Reiterated at HC WainwrightSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 10, 2024 | insidermonkey.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comCytomX Therapeutics, Inc. (CTMX) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | finanznachrichten.deCytomX Therapeutics Inc.: CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 8, 2024 | globenewswire.comCytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateJuly 25, 2024 | msn.comCytomX Therapeutics, Inc. (CTMX): The Best One-Dollar Stock to Buy Now?September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.July 22, 2024 | finance.yahoo.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) is definitely on the radar of institutional investors who own 47% of the companyJune 18, 2024 | globenewswire.comCytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceJune 17, 2024 | globenewswire.comCytomX Therapeutics Promotes Chris Ogden to Chief Financial OfficerMay 29, 2024 | investorplace.comNo Memes, Ma’am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.May 29, 2024 | investorplace.comNo Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.May 29, 2024 | msn.comPiper Sandler Upgrades CytomX Therapeutics (CTMX)May 22, 2024 | globenewswire.comCytomX Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 16, 2024 | globenewswire.comCytomX Therapeutics Announces New Employment Inducement GrantsMay 11, 2024 | wsj.comCytomX Therapeutics Inc.See More Headlines Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTMX CUSIPN/A CIK1501989 Webwww.cytomx.com Phone(605) 515-3185Fax650-351-0353Employees170Year FoundedN/APrice Target and Rating Average Stock Price Target$5.77 High Stock Price Target$8.00 Low Stock Price Target$3.50 Potential Upside/Downside+381.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.20 Trailing P/E Ratio6.00 Forward P/E RatioN/A P/E GrowthN/ANet Income$-570,000.00 Net Margins9.27% Pretax Margin12.61% Return on Equity-27.44% Return on Assets5.78% Debt Debt-to-Equity RatioN/A Current Ratio1.00 Quick Ratio1.00 Sales & Book Value Annual Sales$119.57 million Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value($0.40) per share Price / Book-3.00Miscellaneous Outstanding Shares77,919,000Free Float72,465,000Market Cap$93.50 million OptionableOptionable Beta1.06 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Sean A. McCarthy DPHIL (Age 57)Chairman & CEO Comp: $1.03MKey CompetitorsDURECTNASDAQ:DRRXSelecta BiosciencesNASDAQ:SELBMEI PharmaNASDAQ:MEIPEsperion TherapeuticsNASDAQ:ESPRVoyager TherapeuticsNASDAQ:VYGRView All CompetitorsInsiders & InstitutionsSean A MccarthySold 13,898 sharesTotal: $17,094.54 ($1.23/share)Jeffrey B LandauSold 4,181 sharesTotal: $5,142.63 ($1.23/share)Christopher OgdenSold 1,984 sharesTotal: $2,440.32 ($1.23/share)Forefront Analytics LLCBought 43,176 shares on 8/16/2024Ownership: 0.082%Squarepoint Ops LLCSold 58,311 shares on 8/14/2024Ownership: 0.255%View All Insider TransactionsView All Institutional Transactions CTMX Stock Analysis - Frequently Asked Questions How have CTMX shares performed this year? CytomX Therapeutics' stock was trading at $1.55 at the start of the year. Since then, CTMX shares have decreased by 22.6% and is now trading at $1.20. View the best growth stocks for 2024 here. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) released its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.01. The biotechnology company earned $25.12 million during the quarter, compared to analyst estimates of $21.79 million. CytomX Therapeutics had a net margin of 9.27% and a negative trailing twelve-month return on equity of 27.44%. What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO? 12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend. Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' top institutional shareholders include Acadian Asset Management LLC (3.50%), Assenagon Asset Management S.A. (1.59%), Renaissance Technologies LLC (1.52%) and Congress Park Capital LLC (1.48%). Insiders that own company stock include Sean A Mccarthy, Marcia Belvin, Jeffrey B Landau, Lloyd A Rowland, Christopher Ogden, Amy C Peterson, Carlos Campoy and Elaine V Jones. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE) and SCYNEXIS (SCYX). This page (NASDAQ:CTMX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
